

CSD/BSE&NSE/RPT/2020-21
November 24, 2020

To
The General Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 530239

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")

.....

Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed disclosure of related party transactions on a consolidated basis and balances for the half-year ended September 30th, 2020.

We request you to take this document on your record.

Thanking you,
Yours faithfully,
For **Suven Life Sciences Limited**



Shrenik Soni
Company Secretary
Encl.: as above

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com

Disclosure of related party transactions on a consolidated basis

List of related parties on consolidated basis as per Reg. 23(9)

(a) Holding Company

Jasti Property and Equity Holdings Private Limited
(Holding in its capacity as sole trustee of Jasti Family Trust)

(b) Subsidiary

Suven Neurosciences Inc. (USA)

(c) Key Management personnel (KMP)

Mr. Venkateswarlu Jasti	Chairman & CEO
Mrs. Sudharani Jasti	Whole-time Director
Dr. M. R. Naidu	Independent Director
Prof. Dr. Seyed E. Hasnain	Non-executive Director
Mr. M. Gopalakrishna	Independent Director
Mr. Santanu Mukherjee	Independent Director
Mrs. J.A.S. Padmaja	Independent Director

(d) Entities with common control

Suven Pharmaceuticals Limited
Suven Pharma Inc.

Suven Life Sciences Limited

Transactions during the half-year ended 30th September, 2020 with related parties

Particulars	<i>Rupees in lakhs</i>
	For the half-year ended 30th September 2020
Parent entities	
<ul style="list-style-type: none"> • Jasti Property and Equity Holdings Private Limited (Holding in its capacity as sole trustee of Jasti Family Trust) 	60.00%
Subsidiaries	
<ul style="list-style-type: none"> • Balance outstanding 	25,831.37
Key Management Personnel compensation	
<ul style="list-style-type: none"> • Short term employee benefits • Balance outstanding 	112.87 Nil
Entity with common control	
<ul style="list-style-type: none"> • Rent Expenses • Interest Income on Loan given • Intercorporate Loan to Suven Pharmaceuticals Ltd. <ul style="list-style-type: none"> i. Loan Given ii. Receipts during the half-year towards Loan Given iii. Outstanding Loan at the half-year end • Service Income <ul style="list-style-type: none"> Income from services rendered 	51.79 450.81 0.00 3623.43 9701.82 114.81

Suven Life Sciences Limited